GlaxoSmithKline

• 2024 Targeting NRAS via miR-1304-5p or farnesyltransferase inhibition confers sensitivity to ALK inhibitors in ALK-mutant neuroblastoma

Download
 RDF/XML-Format
 JSON-LD-Format
 Turtle-Format
 N3-Format